56,533 Shares in Establishment Labs Holdings Inc. (NASDAQ:ESTA) Bought by Portolan Capital Management LLC

Portolan Capital Management LLC bought a new stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 56,533 shares of the company's stock, valued at approximately $2,446,000. Portolan Capital Management LLC owned about 0.20% of Establishment Labs as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Maven Securities LTD purchased a new stake in shares of Establishment Labs during the third quarter worth about $433,000. HighTower Advisors LLC raised its holdings in Establishment Labs by 32.5% in the 3rd quarter. HighTower Advisors LLC now owns 10,311 shares of the company's stock valued at $446,000 after acquiring an additional 2,529 shares during the last quarter. Bamco Inc. NY lifted its stake in shares of Establishment Labs by 13.6% during the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company's stock worth $21,176,000 after purchasing an additional 58,611 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Establishment Labs during the 3rd quarter worth $127,000. Finally, Verition Fund Management LLC boosted its holdings in shares of Establishment Labs by 22.8% during the third quarter. Verition Fund Management LLC now owns 9,400 shares of the company's stock worth $407,000 after purchasing an additional 1,746 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on ESTA. BTIG Research increased their target price on Establishment Labs from $62.00 to $65.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Citigroup increased their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a "neutral" rating in a report on Tuesday, October 1st. Stephens raised shares of Establishment Labs to a "strong-buy" rating in a research report on Monday. Finally, JPMorgan Chase & Co. dropped their price target on shares of Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $60.60.

Establishment Labs Trading Down 5.4 %

Shares of Establishment Labs stock traded down $2.38 during trading hours on Thursday, reaching $41.79. The stock had a trading volume of 337,647 shares, compared to its average volume of 387,811. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a 1 year low of $22.05 and a 1 year high of $60.12. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -16.20 and a beta of 1.16. The firm has a 50 day simple moving average of $43.50 and a two-hundred day simple moving average of $44.53.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.